6 days Ago By ABMN Staff
Federated Hermes Inc. purchased a new position in Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD – Free Report ) during the fourth quarter, HoldingsChannel.
com reports. The fund purchased 370,476 shares of the biotechnology company’s stock, valued at approximately $1,641,000. Several other hedge funds and other institutional investors also recently made changes to their positions in IRWD.
State Street Corp lifted its stake in shares of Ironwood Pharmaceuticals by 7.3% in the third quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock worth $40,870,000 after buying an additional 677,024 shares in the last quarter.
Pacer Advisors Inc. lifted its position in Ironwood Pharmaceuticals by 4.0% in the 4th quarter.
Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock valued at $51,967,000 after acquiring an additional 450,949 shares in the last quarter. Los Angeles Capital Management LLC boosted its stake in Ironwood Pharmaceuticals by 2,625.
1% during the 4th quarter. Los Angeles Capital Management LLC now owns 331,700 shares of the biotechnology company’s stock valued at $1,469,000 after purchasing an additional 319,528 shares during the last quarter. Norges Bank bought a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter worth $1,118,000.
Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Ironwood Pharmaceuticals by 170.4% in the fourth quarter.
Connor Clark & Lunn Investment Management Ltd. now owns 341,455 shares of the biotechnology company’s stock worth $1,513,000 after purchasing an additional 215,166 shares during the last quarter. Ironwood Pharmaceuticals Price Performance Shares of IRWD stock opened at $0.
65 on Tuesday. The company has a market cap of $104.84 million, a price-to-earnings ratio of -21.
60 and a beta of 0.30. Ironwood Pharmaceuticals, Inc.
has a 1 year low of $0.59 and a 1 year high of $8.45.
The firm has a fifty day moving average price of $1.52 and a 200-day moving average price of $3.10.
Insiders Place Their Bets In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 139,064 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.
76, for a total value of $244,752.64. Following the completion of the sale, the chief executive officer now owns 1,160,634 shares in the company, valued at approximately $2,042,715.
84. This represents a 10.70 % decrease in their position.
The sale was disclosed in a filing with the SEC, which is accessible through the SEC website . Also, CMO Michael Shetzline sold 41,269 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.
76, for a total value of $72,633.44. Following the completion of the transaction, the chief marketing officer now owns 554,007 shares in the company, valued at $975,052.
32. The trade was a 6.93 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . In the last 90 days, insiders have sold 192,381 shares of company stock worth $338,591. Company insiders own 12.
90% of the company’s stock. Analyst Ratings Changes Several equities research analysts recently commented on the company. Craig Hallum dropped their price objective on Ironwood Pharmaceuticals from $10.
00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. StockNews.
com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 29th. Leerink Partners lowered their price objective on shares of Ironwood Pharmaceuticals from $3.00 to $1.
00 and set a “market perform” rating on the stock in a research report on Monday. JMP Securities cut their target price on shares of Ironwood Pharmaceuticals from $23.00 to $14.
00 and set a “market outperform” rating for the company in a research report on Thursday, January 30th. Finally, Citizens Jmp cut Ironwood Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock.
According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.80. View Our Latest Stock Analysis on IRWD About Ironwood Pharmaceuticals ( Free Report ) Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.
It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. Featured Articles Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc.
( NASDAQ:IRWD – Free Report ). Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
